Orthofix Medical (NASDAQ:OFIX) Releases Earnings Results, Misses Estimates By $0.69 EPS

Orthofix Medical (NASDAQ:OFIX) issued its earnings results on Tuesday. The medical device company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.69), Zacks reports. Orthofix Medical had a negative return on equity of 25.43% and a negative net margin of 15.29%. Orthofix Medical updated its FY 2025 guidance to EPS.

Orthofix Medical Stock Performance

Shares of Orthofix Medical stock opened at $16.06 on Tuesday. The firm has a market capitalization of $634.27 million, a P/E ratio of -5.07 and a beta of 0.89. The company has a quick ratio of 1.50, a current ratio of 2.67 and a debt-to-equity ratio of 0.38. The company has a 50 day moving average price of $14.92 and a 200 day moving average price of $13.00. Orthofix Medical has a 52 week low of $10.24 and a 52 week high of $20.73.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on OFIX. Weiss Ratings reissued a “sell (d-)” rating on shares of Orthofix Medical in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Orthofix Medical from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Barrington Research restated an “outperform” rating and issued a $17.00 price target on shares of Orthofix Medical in a report on Thursday, October 23rd. Finally, Stifel Nicolaus began coverage on shares of Orthofix Medical in a report on Tuesday, October 28th. They issued a “buy” rating and a $22.00 price target on the stock. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Orthofix Medical presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.25.

Hedge Funds Weigh In On Orthofix Medical

Hedge funds and other institutional investors have recently modified their holdings of the stock. Strs Ohio purchased a new position in shares of Orthofix Medical in the 1st quarter valued at approximately $150,000. The Manufacturers Life Insurance Company raised its position in shares of Orthofix Medical by 21.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,867 shares of the medical device company’s stock valued at $166,000 after purchasing an additional 2,589 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Orthofix Medical by 32.6% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 17,550 shares of the medical device company’s stock valued at $196,000 after purchasing an additional 4,314 shares during the last quarter. State of Wyoming raised its position in shares of Orthofix Medical by 85.7% in the 2nd quarter. State of Wyoming now owns 17,657 shares of the medical device company’s stock valued at $197,000 after purchasing an additional 8,150 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in Orthofix Medical by 67.7% during the 1st quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company’s stock worth $333,000 after buying an additional 8,241 shares during the last quarter. 89.76% of the stock is owned by hedge funds and other institutional investors.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.